Courtagen Life Sciences Inc. has raised $8 million in a new funding year, a little more than a year after changing its name from Avantra Biosciences Corp. According to a filing with the U.S. Securities and Exchange Commission, Courtagen has secured a massive 67 investors in the new round, which, when added to the $7 million the company raised when it changed its name last August, brings the total the startup has brought in to approximately $15 million. Listed as a related person in the SEC document is Emery Olcott, a strategic advisor with Courtagen Life Sciences’ parent company, The Courtagen Group LLC. Also listed is Richard Upton of Harbor Light Capital Partners of Keene, N.H., and Philip Chapman, of Palm Beach, Fla.
